← Human Trials & Peer-Reviewed Studies
Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes
Plain-language guide to PMID 26930181 (2016): crossover randomized controlled trial study of Amylin (Islet Amyloid Polypeptide).
Key Facts
- PMID
- 26930181
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Hinshaw L et al. (12 authors)
- DOI
- 10.1210/jc.2015-3952
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Amylin (Islet Amyloid Polypeptide), published as a randomized controlled trial.
Their objective was to investigate the effects of pramlintide, known to suppress glucagon and delay gastric emptying, on postprandial glucose fluxes in T1D.
Why It Was Studied
Early postprandial hyperglycemia and delayed hypoglycemia remain major problems in current management of type 1 diabetes (T1D).
Who Took Part
By PubMed's age tags, the people studied were young adults, adults, middle-aged adults and older adults, both men and women.
This was a single-center, inpatient, randomized, crossover study.
Twelve patients with T1D who completed the study were analyzed.
How the Study Was Run
The researchers set it up as a randomized and crossover study.
Because people in this Amylin (Islet Amyloid Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Each person switched between Amylin (Islet Amyloid Polypeptide) and the comparison at some point, usually with a gap in between.
Triple tracer mixed-meal method and oral minimal model were used to estimate postprandial glucose turnover and insulin sensitivity (SI).
Integrated liver insulin sensitivity was calculated based on glucose turnover.
Plasma glucagon and insulin were measured.
What Was Measured
The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin Resistance, Islet Amyloid Polypeptide and Postprandial Period.
What This Means in Plain Language
The paper is a randomized and crossover study of Amylin (Islet Amyloid Polypeptide).
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2016 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.
Our Notes on the Compound
Amylin (Islet Amyloid Polypeptide): A 37-amino-acid hormone released with insulin that slows stomach emptying and signals fullness; pramlintide (Symlin) is a synthetic version.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.